Most Read

The EC approval allows using Lynparza as a maintenance treatment for adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed

The company is evaluating an agonistic (immunostimulatory) humanised monoclonal antibody, dubbed CPI-006, which is said to show a potential new approach to immunotherapy of infectious diseases and cancer.

The trial is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Regeneron has used

As part of the conditional marketing authorisation, Veklury will be used to treat Covid-19 disease in adults and adolescents, aged 12 years and older and weighing at least

Rukobia is a novel attachment inhibitor, which is designed to treat HIV-1 infection, is specified for use in combination with other antiretroviral (ARV) therapies in heavily treatment-experienced (HTE)

As a result of the approval, Janssen is currently collaborating with the World Health Organisation (WHO) on vaccine pre-qualification to advance the registration of its preventive Ebola vaccine

Phesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, which is administered by subcutaneous injection in combination with intravenous (IV) chemotherapy. Phesgo is said

Theravance is considering that the TD-0903 can block the cytokine storm linked with ALI and prevent progression to acute respiratory distress syndrome (ARDS). According to the company, the

RLF-100 is a synthetic form of human vasoactive intestinal peptide (VIP), which minimises inflammation in the lungs and protects the alveolar type II cells that are considered to